SRR1797274
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.290
- MITOTIC_SPINDLE+0.270
- INTERFERON_ALPHA_RESPONSE+0.240
- OXIDATIVE_PHOSPHORYLATION+0.180
- FATTY_ACID_METABOLISM+0.150
- G2M_CHECKPOINT+0.110
- HEME_METABOLISM+0.090
- UNFOLDED_PROTEIN_RESPONSE+0.080
- E2F_TARGETS+0.070
- ADIPOGENESIS+0.040
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- APICAL_SURFACE-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- ALLOGRAFT_REJECTION-0.270
- TGF_BETA_SIGNALING-0.270
- TNFA_SIGNALING_VIA_NFKB-0.270
- KRAS_SIGNALING_UP-0.210
- MYC_TARGETS_V2-0.210
- IL6_JAK_STAT3_SIGNALING-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03073 | — | cohortA1 | 0.815 |
| 2 | fe4a0710-a6db-4735-9d1a-113df310def6 | — | — | 0.810 |
| 3 | SRR1797242 | — | cohortSC | 0.790 |
| 4 | MNG37 | — | — | 0.788 |
| 5 | BS_EK5PCKY0 | Supratentorial Ependymoma | — | 0.788 |
| 6 | SRR1797246 | — | cohortSC | 0.777 |
| 7 | R151 | — | — | 0.776 |
| 8 | TCGA-C8-A274-01A-11R-A16F-07 | — | B | 0.775 |
| 9 | 004589d9-7eb6-46cb-b822-20cd1939aa7e | — | — | 0.774 |
| 10 | MNG274 | — | — | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.030 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.030 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |